OncoMyx Therapeutics, the latest biotech spinout company from Arizona State University’s Biodesign Institute, announced today it has raised $25 million in new funding to help commercialize an innovative, viral-based therapy for the treatment of cancer.
The announcement marks a major business development milestone for OncoMyx founder, research advisor, and ASU Biodesign scientist Grant McFadden, a pioneer in a new field called oncolytic virotherapy that can successfully program a virus to infect and kill cancer while leaving normal cells unharmed. See full article here.
